Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • STRIIVING study demonstrated that switching from virologically suppressive regimen (2 NRTIs plus PI, NNRTI, or INSTI) to single-tablet, once-daily abacavir/dolutegravir/lamivudine was noninferior to continuing baseline ART for maintenance of virologic suppression at Week 24[Trottier 2017]
  • NEAT-022 study showed that switching virologically suppressed patients with high cardiovascular risk from their current regimen to dolutegravir-based ART was noninferior and improved lipid profiles[Gatell 2017]
  • French study assessed the efficacy and safety of switching virologically suppressed patients from a regimen of dolutegravir plus abacavir/lamivudine (either as separate components or as a coformulated regimen) to bictegravir/emtricitabine/tenofovir AF[Molina 2018]

    Action required

    Keywords: Switch Strategies

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.